Prothena Corporation plc

Healthcare

NASDAQ:PRTA · NASDAQ Global Select

Market Cap $431.91M Beta -0.32 P/E (TTM) -2.9

$8.25 -0.12%

-$0.01 today

52W Low $4.95High $11.80

Vol 0.29M · Avg 0.51M

EPS (TTM)-$2.81

Biotechnology

Filings

Ground the analysis in primary documents

Pair price history with recent company filings so you can connect market moves to the actual disclosures behind the business.

Price History

Dividend-adjusted closing price

Events

Change

+62.40%

Period High

$11.51

Period Low

$5.08

Latest

$8.25

SEC Filings

Recent regulatory filings

No filings found.

Competitors

Peer companies in the same sector

Health

KalVista Pharmaceuticals, Inc.

NASDAQ:KALV

$1.44B

Ventyx Biosciences, Inc.

VTYX

$1.00B

Corvus Pharmaceuticals, Inc.

NASDAQ:CRVS

$1.00B

Olema Pharmaceuticals, Inc.

NASDAQ:OLMA

$862.12M

Rigel Pharmaceuticals, Inc.

NASDAQ:RIGL

$607.79M

4D Molecular Therapeutics, Inc.

NASDAQ:FDMT

$461.60M

Neumora Therapeutics, Inc. Common Stock

NASDAQ:NMRA

$329.81M

Verastem, Inc.

NASDAQ:VSTM

$284.19M

Bicycle Therapeutics plc

NASDAQ:BCYC

$281.05M

Gossamer Bio, Inc.

GOSS

$38.00M

What is the latest PRTA filing?

The latest filing shown is 4 dated Jun 12, 2026.

How many recent filings does PRTA have?

Intrinsic Alpha currently shows 20 recent filings for PRTA.

Explore More

Continue the stock analysis

Jump to another research area for this company.

OverviewStart with valuation, alerts, peers, and the full company snapshot.DCFAdjust assumptions and compare intrinsic value against the market price.FinancialsReview income statement, balance sheet, and cash flow trends.HealthCheck liquidity, leverage, and balance sheet strength.GrowthCompare historical growth, cash generation, targets, and peers.DividendsInspect dividend history, payout durability, and shareholder returns.ManagementReview leadership context, insider activity, and capital efficiency.